Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 5:46 pm Purchase | 2024-09-30 | 13G | Taysha Gene Therapies, Inc. TSHA | RA Capital Management, L.P. | 21,539,465 9.990% | 2,869,376 (+15.37%) | Filing History |
| 2024-11-14 5:46 pm Purchase | 2024-09-30 | 13G | Tenaya Therapeutics, Inc. TNYA | RA Capital Management, L.P. | 7,980,736 9.990% | 1,032,500 (+14.86%) | Filing History |
| 2024-11-14 5:46 pm Purchase | 2024-09-30 | 13G | RxSight, Inc. RXST | RA Capital Management, L.P. | 3,916,825 9.900% | 512,540 (+15.06%) | Filing History |
| 2024-11-14 5:46 pm Purchase | 2024-09-30 | 13G | Sera Prognostics, Inc. SERA | RA Capital Management, L.P. | 3,032,808 9.400% | 985,587 (+48.14%) | Filing History |
| 2024-11-14 5:46 pm Sale | 2024-09-30 | 13G | Structure Therapeutics Inc. GPCR | RA Capital Management, L.P. | 5,690,316 3.300% | -1,534,995 (-21.24%) | Filing History |
| 2024-11-14 5:46 pm Sale | 2024-09-30 | 13G | Third Harmonic Bio, Inc. THRD | RA Capital Management, L.P. | 1,280,826 3.100% | -752,230 (-37.00%) | Filing History |
| 2024-11-14 5:46 pm Purchase | 2024-09-30 | 13G | Tourmaline Bio, Inc. TRML | RA Capital Management, L.P. | 2,538,925 9.900% | 493,897 (+24.15%) | Filing History |
| 2024-11-14 5:46 pm Purchase | 2024-09-30 | 13G | UroGen Pharma Ltd. URGN | RA Capital Management, L.P. | 3,206,271 7.100% | 122,713 (+3.98%) | Filing History |
| 2024-11-14 5:46 pm Purchase | 2024-09-30 | 13G | Unicycive Therapeutics, Inc. UNCY | RA Capital Management, L.P. | 1,047,238 9.990% | 700,027 (+201.61%) | Filing History |
| 2024-11-14 5:46 pm Sale | 2024-09-30 | 13G | Apogee Therapeutics, Inc. APGE | RA Capital Management, L.P. | 1,961,863 3.400% | -16,038 (-0.81%) | Filing History |
| 2024-11-14 5:46 pm Purchase | 2024-09-30 | 13G | Adicet Bio, Inc. ACET | RA Capital Management, L.P. | 519,283 9.990% | 38,224 (+7.95%) | Filing History |
| 2024-11-14 5:46 pm Purchase | 2024-09-30 | 13G | Alto Neuroscience, Inc. ANRO | RA Capital Management, L.P. | 2,075,154 7.700% | 689,663 (+49.78%) | Filing History |
| 2024-11-14 5:46 pm Purchase | 2024-09-30 | 13G | Avidity Biosciences, Inc. RNA | RA Capital Management, L.P. | 6,300,408 5.400% | 1,404,449 (+28.69%) | Filing History |
| 2024-11-14 5:46 pm Purchase | 2024-09-30 | 13G | GH Research PLC GHRS | RA Capital Management, L.P. | 6,686,689 12.900% | 1,099,356 (+19.68%) | Filing History |
| 2024-11-14 5:46 pm Purchase | 2024-09-30 | 13G | Enliven Therapeutics, Inc. ELVN | RA Capital Management, L.P. | 1,061,233 2.200% | 1,061,233 (New Position) | Filing History |
| 2024-11-14 5:46 pm Purchase | 2024-09-30 | 13G | Rhythm Pharmaceuticals, Inc. RYTM | RA Capital Management, L.P. | 6,084,412 9.950% | 754,000 (+14.15%) | Filing History |
| 2024-11-14 5:46 pm Purchase | 2024-09-30 | 13G | Vaxcyte, Inc. PCVX | RA Capital Management, L.P. | 12,649,728 9.990% | 2,964,649 (+30.61%) | Filing History |
| 2024-11-14 5:46 pm Purchase | 2024-09-30 | 13G | Verona Pharma plc VRNA | RA Capital Management, L.P. | 8,460,090 9.990% | 956,114 (+12.74%) | Filing History |
| 2024-11-13 6:04 pm Purchase | 2024-11-08 | 13D | Tyra Biosciences, Inc. TYRA | RA Capital Management, L.P. | 10,677,140 21.100% | 586,069 (+5.81%) | Filing History |
| 2024-11-12 4:15 pm Purchase | 2024-11-04 | 13G | Bright Minds Biosciences Inc. DRUG | RA Capital Management, L.P. | 460,829 6.600% | 460,829 (New Position) | Filing History |